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Abstract. Non-small cell lung cancer (NSCLC) comprises of
75% of all lung cancers. Human full length tissue factor
(flHTF), the physiological initiator of blood coagulation, is
aberrantly expressed in certain solid tumors. FlHTF and its
soluble isoform, alternatively spliced human tissue factor
(asHTF), have been shown to contribute to thrombogenicity of
the blood of healthy individuals. The aim of this study was to
quantify flHTF and asHTF on mRNA and protein levels
(using immunohistochemistry, immunoblotting, and ELISA)
on a panel of human NSCLC tissue and plasma specimens.
The tissue factor (TF) expression of 21 pulmonary
adenomatous (AC) and 12 normal healthy tissues was
assessed by real-time qRT-PCR. The TF protein concentration
was quantified by ELISA in a subset of 11 AC and 9 normal
tissue specimens as well as in the plasma of 13 lung cancer
patients and 15 healthy controls. We found a significant
increase in the ratio of flHTF/HGAPDH mRNA in AC
(0.24±0.06 vs. 0.07±0.01; p=0.02 vs. controls) and in
asHTF/HGAPDH mRNA (0.027±0.01 vs. 0.004±0.001;
p=0.03 AC vs. controls). AsHTF mRNA expression was
significantly lower in patients with stage IA disease
compared to patients with higher grade stages, pointing to TF
as being a marker of malignancy and metastases. TF protein
of lung tumors was significantly increased in AC (p=0.004
vs. controls). TF in plasma was up-regulated in lung cancer
patients (334.9±95.4 vs. 124.1±14.8 pg/ml; p=0.02 vs.
controls). Immunohistochemical and immunoblotting data
are in line with the increased TF expression, showing
elevated blood thrombogenicity of NSCLC patients. The up-
regulation of flHTF and, especially, asHTF in AC suggests
not only a raised risk of thrombosis, but also of tumor
progression, thereby, indicating a poor prognosis in these
patients.
Introduction
In the western world, lung cancer is the leading cause of
cancer death in men. Lung cancers are classified into several
groups, including small-cell lung cancer (SCLC) and non-
small cell lung cancer (NSCLC). NSCLC comprises of 75%
of all lung cancers. The reason why lung cancer is frequently
lethal is that most of the patients are diagnosed in the later
stages of the disease, when local infiltrations and metastases
are detected and malignancy is incurable. In contrast, outcomes
are significantly better if the disease can be detected at an
earlier stage, enabling curative resections (1,2).
Tissue factor (TF), a transmembrane glycoprotein
comprising of 263 amino acids, plays a key role as a cellular
receptor and cofactor of the coagulation factor VII/VIIa,
initiating blood coagulation (3,4). TF is not only present in the
adventitia of the vessel wall but also in circulating blood,
thereby increasing blood thrombogenicity. In vitro studies on
the expression of thrombogenic TF showed a secretion of
TF-positive microparticles from smooth muscle cells,
endothelial cells and monocytes in response to several
inflammatory stimuli (3-8). Furthermore, a human
alternatively spliced TF isoform (asHTF) in addition to the
full length TF (flHTF) was detected in lung tissue. This
isoform lacks exon 5, which encodes the transmembrane TF
domain. AsHTF is a soluble form of the TF protein and
circulates in blood, possibly contributing to blood thrombo-
genicity as well as angiogenesis (9). Up-regulated levels of
circulating TF antigen were found in patients with solid
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tumors and disseminated vascular disease (DIC) (10,11). Up-
regulated TF levels in the plasma of tumor patients, especially
in carcinomas of the pancreas, mamma and lung were
associated with an increased rate of thrombotic events
(10,12). Moreover, experimental studies showed TF
expressing tumor tissues to reveal a more aggressive
metastasis formation (13). It has been shown that TF
expression in NSCLC cells is associated with vascular
endothelial growth factor (VEGF) expression and increased
microvessel density. The survival time for patients with
immunologically TF-negative NSCLC tumors is longer than
with TF-positive tumors (13).
The aim of this study was to quantify the TF isoform
expression on mRNA and protein levels with a particular
focus on the soluble TF isoform asHTF in adenocarcinoma of
the lung. Furthermore, the present study was performed in
order to examine the value of the TF isoform expression as a
marker of lung cancer stage and progression on a panel of
human lung adenocarcinomas and corresponding normal,
healthy tissues as well as the plasma of lung cancer patients
and healthy controls.
Materials and methods
Patients and tumors. Twenty-one patients with adeno-
carcinomas of the lung and 12 normal healthy control tissues
of the lung underwent surgery at the Charité-Universitäts-
medizin Berlin, Campus Benjamin Franklin. Each patient
gave written informed consent. The histological classification
of the tumors was based on the World Health Organization
Study (14) and was carried out by two pathologists. Each
tumor was staged at the time of their surgery according to the
guidelines of the International Union Against Cancer (15).
Clinical information was obtained from a review of
hospital charts or from the respective hospital tumor registry.
The study was approved by the Ethics Committee of the
Charité University Hospital.
TF isoform-specific real-time PCR (Taq Man). Total RNA of
human NSCLC tissue specimens was isolated by the TRIzol
method according to manufacturer's instructions (Invitrogen,
Karlsruhe, Germany), reverse transcribed including a control
without Reverse Transcriptase (First Strand cDNA synthesis
kit for RT-PCR [AMV]) to exclude a generation of genomic
DNA and analyzed by PCR using primers as previously
described (16).
Western blot. Samples from human lung AC tissues were
homogenized in a radio-immunoprecipitation assay buffer,
supplemented with 1% protease inhibitor cocktail (P-8340,
Sigma Aldrich, Munich, Germany) and were separated by
electrophoresis on a 12% sodium dodecyl sulfate-poly-
acrylamide gel (SDS-PAGE). The gels were transferred to a
PVDF membrane (Immobilon-P, Millipore GmbH,
Schwalbach, Germany), which was blocked in 5% nonfat dry
milk diluted in tris-buffered saline. Blots were incubated at
4˚C overnight with the primary polyclonal anti-TF antibody
(pAb-sTF, 6 μg/ml) (16). Washed blots were incubated for
90 min with a secondary horseradish peroxidase-conjugated
antibody (DakoCytomation, Hamburg, Germany). Washed
blots were subjected to the ECL Plus Western blotting
detection reagent (Amersham, Freiburg, Germany) for
detection of the immunoreactive signal by chemiluminescence
and the membranes were then exposed to X-ray film (Kodak
X-OMAT AR, Kodak, Stuttgart, Germany). The membranes
were stripped in 100 mM glycine (pH 2.9) at room
temperature for 45 min. The stripped blots were blocked
again for 1 h and incubated with a primary polyclonal
antibody anti-asHTF (dilution at 1:100, Pineda Antikörper-
Service) (16). After incubation, the blots were washed and
treated as described. The membrane was then exposed to X-
ray film.
Protein extraction and TF ELISA. Human lung cancer tissue
samples were homogenized in a glass potter containing 100 μl
ice-cold radio-immunoprecipitation assay buffer, supplemented
with 1% protease-inhibitor cocktail, incubated on ice for
30 min and centrifuged at 10,000 x g for 10 min at 4˚C. Total
protein content of the cell lysate was measured using a
bicinchoninic acid protein assay according to the
manufacturer's protocol (Pierce, Rockford, IL). The protein
was precipitated with acetone and afterwards re-suspended in
TBS (pH 8.5). To quantify the total TF protein content (flHTF
and asHTF) in the tumor specimens, TF ELISA was performed
according to the instruction manual (Imubind tissue factor
ELISA kit, American Diagnostica Inc.). Separate plasma
aliquots obtained from lung cancer patients and healthy
subjects were quickly thawed and utilized for the Imubind
tissue factor ELISA kit (American Diagnostica Inc., Stamford,
CT).
Immunohistochemistry. A total of 12 patients with adeno-
carcinomatous lung cancer who underwent lung resection were
studied. Histological diagnoses were made on the basis of
sections stained with haematoxylin and eosin. The TNM
classification is used internationally for malignant tumors and
is accepted by the American Joint Committee on Cancer
(AJCC) and the Union Internationale Contre le Cancer (UICC)
(17,18). The specimens were compared with negative controls.
The results were graded as follows: negative (0), moderately
positive (1), positive (2) and strongly positive (3).
For flHTF and asHTF isoform staining, specimens were
immediately snap-frozen and stored at -80˚C. Cryostat sections
were washed with phosphate-buffered saline (PBS), incubated
in 4% H2O2 and immunostained either with polyclonal rabbit
anti-human antibody against sTF (American Diagnostica Inc.),
diluted at 1:75 in PBS/fetal calf serum, or with polyclonal
rabbit anti-human antibody against asHTF (diluted at 1:50),
respectively. A second polyclonal antibody specific for
asHTF as previously described (16) was used for staining.
After incubation with the primary antibody, specimens were
washed, incubated with an appropriate biotinylated
secondary antibody (DakoCytomation) and counterstained
with haematoxylin (Merck, Darmstadt, Germany). For
detection, the Vectastain ABC kit was used according to the
manufacturer's instructions (Vector Laboratories, Burlingame,
CA).
Statistical analysis. Data analysis was performed using
GraphPad Prism 4.0 for Windows. To test data distribution
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the Kolmogorov-Smirnov test was performed. Values are
represented as mean ± standard error of mean (SEM) or
median and interquartile range for non-parametric data. For
parametric data, the statistical significance of differences
between the groups was determined by applying an unpaired
Student's t-test. The Mann-Whitney U test was performed for
non-parametric data. The Chi-square test evaluated the
association between the low TF group and the high TF group
with tumor characteristics. We determined the cut-off for high
and low TF groups on the basis of flHTF and asHTF mRNA
expression. P≤0.05 was considered significant.
Results
Elevated TF mRNA expression in lung adenocarcinomas. A
total of 21 human adenocarcinomas (AC) and 12 normal
human tissues were examined for mRNA expression of flHTF,
asHTF and human glyceraldehyde-3-phosphate dehydrogenase
(HGAPDH) genes using quantitative real-time RT-PCR
(qRT-PCR). A 3.4-fold increase of mRNA expression was
yielded in AC vs. control specimens (ratio flHTF/ HGAPDH
0.24±0.06 vs. 0.07±0.01; p=0.02 vs. controls) (Fig. 1A). The
ratio asHTF/HGAPDH in AC (0.027±0.01 vs. 0.004±0.001;
p=0.03 vs. controls) was 6.8-fold raised compared with the
controls (Fig. 1B).
Patient characteristics of flHTF and asHTF mRNA expression
groups. A total of 21 patients were divided into two groups
with a cut-off value of flHTF/HGAPDH ratio of 0.08 and
asHTF/HGAPDH ratio of 0.008. The flHTF group and
asHTF groups, respectively, were determined according to the
mRNA expression analysis by real-time qRT-PCR. Mean age
of the lung cancer population at the time of analysis was
65.6±0.6 years (range 41-82 years). Fourteen patients were
male and 7 were female. A majority of AC patients in the
high flHTF group (58.3%) and 54.5% of the high asHTF
group patients had stage II to IV cancers. Ten out of 21
(47.6%) had lymph node metastases. Nine out of 21 (42.9%)
patients with AC revealed recurrent disease after surgery
(Table I). FlHTF mRNA expression was not significantly
altered between the flHTF groups (Table IA). In contrast,
asHTF mRNA expression was significantly lower in patients
with stage IA disease compared to patients with higher grade
stages (p≤0.01 vs. stage IIIA, IIIB) (Table IB).
Immunohistochemistry of adenocarcinomas of the lung.
Snap-frozen lung cancer tissues of 12 patients were examined
by immunohistochemistry for human flHTF and asHTF. Eight
out of 12 AC (66.7%) were moderately positive for flHTF
protein expression. One of the 12 AC revealed a strongly
positive asHTF expression whereas throughout a moderately
positive staining in 11 out of 12 tumors (91.7%) with the
asHTF-specific antibody was observed vs. the overall negative
control healthy tissue.
Western blot analysis of lung cancer tumor specimens with TF
full length- and TF isoform-specific antibodies. FlHTF and
asHTF were detected by polyclonal anti-TF antibodies
(pAb-sTF, 6 μg/ml) directed against the extracellular domain
of the TF protein (Fig. 3) yielding a single protein band at
46 kDa (Fig. 3A, lanes 1 and 2) for flHTF and at 28 kDa for
asHTF (Fig. 3B, lanes 1 and 2). For equal loading of the
protein, HGAPDH expression was shown in Fig. 3C. FlHTF
protein expression in AC compared to the healthy control
was increased. AsHTF was detected in AC, though not in
normal, healthy controls.
Up-regulation of TF protein concentration in lung
adenocarcinoma specimens and corresponding healthy control
tissues. A significant increase in cellular TF protein
measured by TF ELISA became prominent in AC (n=11) with
a TF level of 1119.0±210.3 pg/ml (p=0.004) compared to
healthy control tissue specimens (n=9) with a TF level of
324.0±92.5 pg/ml (Fig. 2B). TF protein expression in the
plasma of NSCLC tumor patients (n=13) was demonstrated
to be significantly up-regulated with TF protein levels of
334.9±95.44 vs. 124.1±14.79 pg/ml (p=0.02) in the healthy
controls (n=15).
Discussion
In the present study, we demonstrated flHTF and especially
asHTF mRNA expression and TF protein levels in lung AC
tissues compared to healthy tissues to be significantly elevated.
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Figure 1. mRNA expression of flHTF (A) and asHTF (B) of AC vs. normal healthy (N) lung control tissues. (A) N vs. AC: p=0.02 (n=12-21). (B) N vs. AC:
p=0.03 (n=12-21).
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Furthermore, in addition to the significant increase in
intratumoral TF protein, plasma TF levels of patients with AC
increased when compared to the plasma of the healthy
controls.
Immunostaining for TF revealed lung carcinomas, such as
bronchoalveolar cell carcinomas and small-cell lung cancer to
express TF irrespective of their location (17). Neoplastic cells
invading the basement membrane or completely obliterating
the alveolar architecture stained at the same intensity as those
confined to the bronchial mucosa (17). Volm et al (18)
reported the expression of the TF protein to be significantly
higher in AC compared to SCC of NSCLC. Sawada et al (19)
found human NSCLC cell lines derived from metastatic cells
producing high levels of TF in vitro. Furthermore, they studied
surgically-resected specimens and found significantly stronger
staining for TF in NSCLC specimens with metastases than in
those without. Koomagi and Volm (13), in contrast, did not
find any correlation to metastasis in lung cancer patients. A
significant association between TF expression and high
microvessel density was observed in several tumor types
including lung cancers. Moreover, patients with TF-positive
lung carcinomas were found to have shorter survival times
than patients with TF-negative carcinomas (13). The studies
with NSCLC tumors are based on immunohistochemistry and
describe the TF protein expression without distinguishing
between the two TF isoforms, flHTF and asHTF.
To date, little is known about the impact of asHTF in
human lung cancer. AsHTF is a protein soluble in aequeous
solutions, though the functional activity and the biological
relevance still remain unclear. In our study, the TF levels in the
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Figure 3. Representative Western blot analysis of human NSCLC tumor
specimens. (A) flHTF protein expression of human AC tumor specimens
detected with the polyclonal anti-TF antibody (pAb-sTF), lane 1, healthy
control; lane 2, AC. (B) AsHTF protein expression of human AC tumor
specimens detected with the polyclonal anti-asHTF antibody, lane 1, healthy
control; lane 2, AC. (C) Human GAPDH protein expression as loading
control of equal protein amounts, lane 1, healthy control; lane 2, AC.
Figure 2. (A) Cryopreserved sections of human adenocarcinomas (AC) of the lung. (a) Normal healthy human lung tissue (magnification, x400). (b) AC
stained with psTF Ab (magnification, x200). (c) AC stained with asTF Ab (magnification, x400). (B) Intratumoral concentrations of total TF antigen in
normal control tissues (N) and adenocarcinomas of the lung (AC). N vs. AC: p=0.004 (n=9-11).
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tumor itself were at least 3-fold higher than in the normal
controls. It is known that levels of TF plasma are elevated in
cancer patients and experimental studies have shown that TF
may contribute to thrombus formation (3,20). TF plasma
concentrations in patients with AC of the lung were found to
be on average 2.7-fold that of normal controls. TF in blood
may derive from asHTF or from flHTF-containing micro-
particles (MPs), which is secreted by activated cells, thereby
contributing to systemic thrombogenicity. It has been
reported that MPs bearing active TF are released readily from
tumor cells and can significantly activate coagulation even at
low concentrations (21). Recently, we showed that human
asHTF is expressed and the expression is up-regulated in
squamous cell carcinoma of the lung (22). Beuneu et al (23)
reported asHTF mRNA to be expressed in a human adeno-
carcinomatous pancreatic duct cell line. They hypothesized
that procoagulant activity measured in the supernatant of
duct cells was ascribed to asHTF as well as TF-bearing
microparticles (MPs) (23). In vitro experiments on colo-
rectal and squamous cell carcinoma revealed the shedding of
TF-positive MPs rather than soluble TF isoform, asHTF, to
be the main source of TF released from human cancer cells
(12). In addition to the two known TF isoforms, a novel
human TF splice variant has recently been described to be
present in tumor cells. Approximately 10% of the total TF
transcripts in the tumor consisted of this novel TF variant
(TF-A) formed by the insertion of a 495 bp sequence, referred
to as exon IA, which is derived from an internal sequence of
the first intron (24). However, the novel TF mRNA transcript
TF-A was found to be differentially expressed in various
tumor cells. Hence, its suitability as a diagnostic marker for
solid tumors has been considered, though has not yet been
verified.
Recent studies have shown that asHTF-positive tumors
seem to have increased vascular density compared with
controls, suggesting a role of asHTF as promoting angio-
genesis. AsHTF was postulated to be the more important TF
isoform in the enhancement of tumor growth (25) TF, though
not flHTF, enhances tumor growth and tumor-associated
vasculature (25). In line with our data, asHTF expression was
only seen in patients with an AC tumor of a higher advanced
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Table I. Patient characteristics.
–––––––––––––––––––––––––––––––––––––––––––––––––
A, Low and high flHTF groups
–––––––––––––––––––––––––––––––––––––––––––––––––
Low flHTF group High flHTF group
–––––––––––––––––––––––––––––––––––––––––––––––––
flHTF/HGAPDH flHTF/HGAPDH
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B, Low and high asHTF groups.
–––––––––––––––––––––––––––––––––––––––––––––––––
Low asHTF group High asHTF group
–––––––––––––––––––––––––––––––––––––––––––––––––
asHTF/HGAPDH asHTF/HGAPDH
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AC, Adenocarcinoma of the lung; LN (-), lymph node negative; LN (+), lymph
node positive; n.e., not evaluable; ap≤0.01 (vs. IIIA, IIIB).
–––––––––––––––––––––––––––––––––––––––––––––––––
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stage than IA. TF expression in cancer tissue has been
suggested to enhance the transcription of VEGF, which
stimulates angiogenesis thus playing a role in the cellular
signalling involved in the tumor growth and metastatic
potential of certain cancers (26). To gain a deeper knowledge
of the mechanisms and pathways, the role of TF as a general
marker of activated endothelium in pathological angiogenesis
and the phosphorylation state of cellular TF, in particular in
invasive areas of the carcinoma, should be further examined
(27).
In conclusion, this study demonstrated that flHTF and, at
least to the same degree, asHTF may serve as a risk factor in
lung cancer patients. Further investigation with a larger sample
size will be needed to evaluate whether specific TF isoforms in
tumors and tumor-associated blood vessels may present targets
for anti-cancer drug design.
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